Literature DB >> 33531581

Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma.

Michael R Moore1, Isabel D Friesner2, Emanuelle M Rizk1, Jing Wang3,4, Rami Vanguri5, Yvonne M Saenger6, Benjamin T Fullerton1, Manas Mondal1, Megan H Trager7, Karen Mendelson8, Ijeuru Chikeka9, Tahsin Kurc10, Rajarsi Gupta10, Bethany R Rohr11, Eric J Robinson12, Balazs Acs13,14, Rui Chang15, Harriet Kluger16, Bret Taback17, Larisa J Geskin9, Basil Horst18, Kevin Gardner19, George Niedt9, Julide T Celebi8, Robyn D Gartrell-Corrado20, Jane Messina21, Tammie Ferringer22, David L Rimm13, Joel Saltz10.   

Abstract

Accurate prognostic biomarkers in early-stage melanoma are urgently needed to stratify patients for clinical trials of adjuvant therapy. We applied a previously developed open source deep learning algorithm to detect tumor-infiltrating lymphocytes (TILs) in hematoxylin and eosin (H&E) images of early-stage melanomas. We tested whether automated digital (TIL) analysis (ADTA) improved accuracy of prediction of disease specific survival (DSS) based on current pathology standards. ADTA was applied to a training cohort (n = 80) and a cutoff value was defined based on a Receiver Operating Curve. ADTA was then applied to a validation cohort (n = 145) and the previously determined cutoff value was used to stratify high and low risk patients, as demonstrated by Kaplan-Meier analysis (p ≤ 0.001). Multivariable Cox proportional hazards analysis was performed using ADTA, depth, and ulceration as co-variables and showed that ADTA contributed to DSS prediction (HR: 4.18, CI 1.51-11.58, p = 0.006). ADTA provides an effective and attainable assessment of TILs and should be further evaluated in larger studies for inclusion in staging algorithms.

Entities:  

Year:  2021        PMID: 33531581     DOI: 10.1038/s41598-021-82305-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  31 in total

1.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Authors:  Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert
Journal:  N Engl J Med       Date:  2018-04-15       Impact factor: 91.245

2.  Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Authors:  Nancy E Thomas; Klaus J Busam; Lynn From; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Pamela A Groben; Honglin Hao; Irene Orlow; Anne S Reiner; Li Luo; Susan Paine; David W Ollila; Homer Wilcox; Colin B Begg; Marianne Berwick
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

3.  The N-terminal region of Escherichia coli lactose permease mediates membrane contact of the nascent polypeptide chain.

Authors:  U Stochaj; R Ehring
Journal:  Eur J Biochem       Date:  1987-03-16

4.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

5.  Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

Authors:  S J O'Day; M Maio; V Chiarion-Sileni; T F Gajewski; H Pehamberger; I N Bondarenko; P Queirolo; L Lundgren; S Mikhailov; L Roman; C Verschraegen; R Humphrey; R Ibrahim; V de Pril; A Hoos; J D Wolchok
Journal:  Ann Oncol       Date:  2010-02-10       Impact factor: 32.976

6.  Cost differential of immuno-oncology therapy delivered at community versus hospital clinics.

Authors:  Lucio Gordan; Marlo Blazer; Vishal Saundankar; Denise Kazzaz; Susan Weidner; Michael Eaddy
Journal:  Am J Manag Care       Date:  2019-03-01       Impact factor: 2.229

7.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

Authors:  Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Lars Bastholt; Laurent Mortier; Luc Thomas; Saad Tahir; Axel Hauschild; Jessica C Hassel; F Stephen Hodi; Corina Taitt; Veerle de Pril; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

Review 8.  Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.

Authors:  Nayoung Lee; Labib R Zakka; Martin C Mihm; Tobias Schatton
Journal:  Pathology       Date:  2016-01-16       Impact factor: 5.306

9.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Authors:  Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

10.  A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.

Authors:  Jeffrey Weber; John A Thompson; Omid Hamid; David Minor; Asim Amin; Ilan Ron; Ruggero Ridolfi; Hazem Assi; Anthony Maraveyas; David Berman; Jonathan Siegel; Steven J O'Day
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

View more
  4 in total

Review 1.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

2.  Development of an Image Analysis-Based Prognosis Score Using Google's Teachable Machine in Melanoma.

Authors:  Stephan Forchhammer; Amar Abu-Ghazaleh; Gisela Metzler; Claus Garbe; Thomas Eigentler
Journal:  Cancers (Basel)       Date:  2022-04-29       Impact factor: 6.575

Review 3.  Multiplexed Immunohistochemistry and Digital Pathology as the Foundation for Next-Generation Pathology in Melanoma: Methodological Comparison and Future Clinical Applications.

Authors:  Yannick Van Herck; Asier Antoranz; Madhavi Dipak Andhari; Giorgia Milli; Oliver Bechter; Frederik De Smet; Francesca Maria Bosisio
Journal:  Front Oncol       Date:  2021-03-29       Impact factor: 6.244

4.  An integrative approach of digital image analysis and transcriptome profiling to explore potential predictive biomarkers for TGFβ blockade therapy.

Authors:  Robert Pomponio; Qi Tang; Anthony Mei; Anne Caron; Bema Coulibaly; Joachim Theilhaber; Maximilian Rogers-Grazado; Michele Sanicola-Nadel; Souad Naimi; Reza Olfati-Saber; Cecile Combeau; Jack Pollard; Tun Tun Lin; Rui Wang
Journal:  Acta Pharm Sin B       Date:  2022-03-25       Impact factor: 14.903

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.